Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valacyclovir in Infants at Risk of Acquiring Neonatal Herpes Simplex Virus Disease
NCT05468619Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2023
- Primary completion
- Jun 2025
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of valaciclovir in herpes simplex (HSV) (2 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Area Under the Concentration-Time Curve From 0 to 12 Hours of Acyclovir in Plasma. Started Aug 2023; status: completed.
02
Drugs
valaciclovir
03
Conditions
herpes simplex (HSV)
Beyond the preview
Go deeper on NCT05468619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05468619.